All Stories

  1. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

    Article • British Journal of Haematology, October 2015, Wiley

    Dr DEEPIKA S DAS